Clinical trials
Liver Carcinoma clinical trials
Below are recruiting liver carcinoma clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07042919RecruitingPhase 1/Phase 2
Zanzalintinib for advanced liver cancer after prior treatment
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Chicago, IllinoisAges 18 years+ - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT07062380Recruiting
AI tool to predict liver cancer return after surgery
This study uses an AI tool to predict how liver cancer might come back after surgery. It is for people with early-stage liver cancer who are already scheduled for surgery and have recent MRI scans.
Wuhan, HubeiAges 18–75 - NCT07059494RecruitingPhase 4
Combination therapy for liver cancer before transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
New York, New YorkAges 18 years+ - NCT06764316RecruitingPhase 1
Safety study of BAY 3547926 for advanced liver cancer
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Dothan, AlabamaAges 18 years+ - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT05323201RecruitingPhase 1/Phase 2
B7H3 CAR-T therapy for advanced liver cancer
This trial tests an immune therapy made from your own blood cells (CAR-T) to treat advanced, unresectable liver cancer. It’s designed for people whose tumor has a specific marker called B7H3 and who meet blood, organ, and safety requirements.
Xuzhou, JiangsuAges 18–70 - NCT05331911RecruitingPhase 4
Propofol anesthesia vs sevoflurane for liver tumor surgery
This study compares two types of general anesthesia—propofol-based total intravenous anesthesia versus sevoflurane inhaled anesthesia—during planned surgery to remove liver tumors. The goal is to see whether the anesthesia choice affects long-term outcomes after partial liver removal for hepatocellular carcinoma.
Kaohsiung CityAges 20–80 - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65 - NCT05971108Recruiting
Check a blood test system to catch liver cancer early
This study will test a real-world blood testing system (Elecsys GAAD) to improve surveillance and earlier detection of liver cancer in people who already have liver scarring (cirrhosis). If it works well, it could help find liver cancer sooner and potentially improve outcomes.
Manchester, Greater ManchesterAges 18 years+ - NCT06007846RecruitingPhase 2/Phase 3
Memantine for advanced liver cancer and cirrhosis
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
Fairfax, VirginiaAges 18 years+ - NCT06015022RecruitingPhase 2
Green tea extract to prevent liver cancer in cirrhosis
This trial tests whether a green tea extract called EGCG can prevent liver cancer in people with cirrhosis. It looks at how the extract affects liver cell changes that could lead to cancer.
Dallas, TexasAges 18 years+ - NCT06061276Recruiting
Combined therapy for large liver cancer with limited spread
This trial tests a combination of treatments—bland transarterial embolization (bTAE), hepatic artery infusion chemotherapy (HAIC), and systemic therapy—for people with large liver cancers that have limited spread. It might be an option if you have a big tumor and your liver is still working well.
Guanzhou, GuangdongAges 18–75 - NCT06418165Recruiting
Cooled oxygenated machine perfusion for liver transplant
This study tests a new way to preserve donated livers using a machine that keeps the organ cool and oxygenated before transplant. It may help improve how well the liver works after the surgery.
ViennaAges 18 years+ - NCT06877637Recruiting
Tracking bile duct and liver cancer during treatment
This study tracks how bile duct and liver cancers change during treatment, to help doctors find the best therapies for patients. It is for people who are newly diagnosed or starting a new treatment.
KristianstadAges 18 years+ - NCT06898398Recruiting
TACE before surgery for large liver cancer
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06899854Recruiting
Collecting blood and tissue from patients with liver cancer
This study collects blood and tumor tissue samples from people with primary liver cancer who are starting their first treatment (systemic therapy or surgery). The samples help researchers learn more about these cancers and how to improve future treatments.
Pavia, PaviaAges 18–90 - NCT06914648Recruiting
Liver preparation before surgery study for certain liver cancers
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
New Haven, ConnecticutAges 18 years+ - NCT02174549RecruitingPhase 1/Phase 2
Testing a drug with liver artery treatment for liver-spread neuroendocrine cancer
This early-stage study tests a cancer drug called tirapazamine, given along with a liver artery procedure (embolization) to treat liver-dominant metastatic neuroendocrine tumors. It aims to find a safe dose and see whether the combination can better control tumor growth in the liver.
Palo Alto, CaliforniaAges 20–99 - NCT07500220RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for advanced liver cancer
This trial tests a new cell therapy made from natural killer (NK) cells that are engineered to attack two targets (GPC3 and B7-H3) found on liver cancer cells. It may be an option for people with advanced liver cancer who have already tried standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+ - NCT06715839Recruiting
Digestive cancer imaging study with targeted antibodies
This trial uses a special imaging test (PET scan) to find digestive system cancers. It uses molecules that attach to cancer cells so they light up on the scan, which may help doctors see tumors more clearly.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+ - NCT05791448RecruitingPhase 1
AU409 for advanced liver cancers or liver-spread tumors
This Phase 1 trial studies AU409, a new medicine, for advanced primary liver cancers or other solid tumors mainly in the liver. It aims to find a safe dose and see how well the treatment works for people whose usual options have not worked or are not available.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Liver Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver carcinoma?
- Yes. Clin2 currently lists 177 recruiting liver carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.